Marinus pushes on despite mid-stage doubts
The group’s determination to conquer another rare epilepsy, tuberous sclerosis complex, looks questionable.
Smaller companies set for third-quarter catalysts
The third quarter will see important data for Travere, Radius and Sio Gene, among other small developers.
First-quarter catalysts for the smaller players
Important data releases are on the cards for Rhythm, Wave and Supernus, among others.
Biogen’s Sage advice amounts to $1.5bn
Sage gets a big endorsement for zuranolone, but the markets say it should have waited until it had a stronger negotiating position.
Marinus finds a path forward in rare epilepsies
Marinus celebrates pivotal trial success with ganaxolone, but a quick approval could depend on lenient regulators.
First fragile X test is approved, and Zynerba could benefit
The fragile X pipeline is strewn with failures, and crunch time is approaching for Zynerba’s cannabinoid.
Marinus leaves the way clear for Sage
In the wake of a clinical trial failure Marinus plays down oral ganaxolone, but investors are unimpressed.
